ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Jedd Wolchok, MD, PhD, Summarizes Results From the CheckMate 067 Trial in Advanced Melanoma

Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).

Sarcoma

Patrick Schöffski, MD

Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).

Global Cancer Care

Gynecologic Cancers

Eduardo Cazap, MD, PhD and James O. Armitage, MD

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Eduardo Cazap, MD, PhD, of the Latin American & Caribbean Society of Medical Oncology, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss oncology from an international point of view.

Head and Neck Cancer

Anil D’Cruz, MD

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Anil D’Cruz, MD, of Tata Memorial Hospital, discusses results from his study that seem to resolve a 50-year-long debate on performing elective neck dissection at the time of primary surgery––a potentially practice-changing finding (Abstract LBA3).

Breast Cancer

Nicholas C. Turner, MD, PhD, and Clifford A. Hudis, MD

Nicholas C. Turner, MD, PhD, and Clifford A. Hudis, MD, on Results of the PALOMA3 Study on Hormone Receptor–Positive, HER2 Negative Metastatic Breast Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discuss fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed on prior endocrine therapy (Abstract LBA502).

Jul

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Jedd Wolchok, MD, PhD, Summarizes Results From the CheckMate 067 Trial in Advanced Melanoma

Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Nicholas C. Turner, MD, PhD, and Clifford A. Hudis, MD, on Results of the PALOMA3 Study on Hormone Receptor–Positive, HER2 Negative Metastatic Breast Cancer

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Single-Fraction SBRT in Localized Prostate Cancer

Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy

FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma